Human Oncology and Pathogenesis Program,
Department of Medicine,
Human Oncology and Pathogenesis Program, Department of Medicine
Omar Abdel-Wahab has not added Biography.
If you are Omar Abdel-Wahab and would like to personalize this page please email our Author Liaison for assistance.
Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution.
Cellular immunology Aug, 2003 | Pubmed ID: 14609574
Immunotherapy of surgical malignancies.
Current problems in surgery Jan, 2004 | Pubmed ID: 14749625
Modulation of resistance to regional chemotherapy in the extremity melanoma model.
Surgery Aug, 2004 | Pubmed ID: 15300182
In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
Journal of the American College of Surgeons Sep, 2004 | Pubmed ID: 15325612
The role of hyperthermia in regional alkylating agent chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2004 | Pubmed ID: 15355925
Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses.
The Journal of surgical research Apr, 2005 | Pubmed ID: 15820257
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research Jan, 2006 | Pubmed ID: 16397054
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Molecular cancer therapeutics Mar, 2006 | Pubmed ID: 16546988
Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature.
Transfusion May, 2006 | Pubmed ID: 16686841
Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities.
Transfusion Aug, 2006 | Pubmed ID: 16934060
An 87-year-old woman with respiratory distress and alveolar hemorrhage after transfusion.
Chest Nov, 2006 | Pubmed ID: 17099045
Functional evaluation of the grafted wall with porcine-derived small intestinal submucosa (SIS) to a stomach defect in rats.
Surgery Sep, 2007 | Pubmed ID: 17723890
Primary myelofibrosis: update on definition, pathogenesis, and treatment.
Annual review of medicine , 2009 | Pubmed ID: 18947294
Warfarin-induced skin necrosis in a patient with heparin-induced thrombocytopenia: two diseases or one?
Acta haematologica , 2008 | Pubmed ID: 19018128
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Blood Jul, 2009 | Pubmed ID: 19420352
Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms.
American journal of hematology Jan, 2010 | Pubmed ID: 19957346
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Cancer research Jan, 2010 | Pubmed ID: 20068184
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Blood Apr, 2010 | Pubmed ID: 20154217
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Cancer cell Mar, 2010 | Pubmed ID: 20171147
Metabolism and the leukemic stem cell.
The Journal of experimental medicine Apr, 2010 | Pubmed ID: 20368582
Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera.
Blood Oct, 2010 | Pubmed ID: 20585043
Recent advances in the treatment of acute myeloid leukemia.
F1000 medicine reports , 2010 | Pubmed ID: 20798782
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia.
Cancer cell Sep, 2010 | Pubmed ID: 20832754
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.
The Journal of clinical investigation Oct, 2010 | Pubmed ID: 20852385
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.
Proceedings of the National Academy of Sciences of the United States of America Oct, 2010 | Pubmed ID: 20864632
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Cancer cell Dec, 2010 | Pubmed ID: 21130701
ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition.
Haematologica Feb, 2011 | Pubmed ID: 21193423
Genetics of the myeloproliferative neoplasms.
Current opinion in hematology Mar, 2011 | Pubmed ID: 21307773
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation.
Cancer cell Feb, 2011 | Pubmed ID: 21316606
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.
The Journal of biological chemistry Jul, 2011 | Pubmed ID: 21532034
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.
Nature May, 2011 | Pubmed ID: 21562564
Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML.
Blood Jul, 2011 | Pubmed ID: 21653321
Clinical effect of point mutations in myelodysplastic syndromes.
The New England journal of medicine Jun, 2011 | Pubmed ID: 21714648
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.
Cancer cell Jul, 2011 | Pubmed ID: 21723200
Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy.
Advances in hematology , 2012 | Pubmed ID: 21811504
TET family proteins and their role in stem cell differentiation and transformation.
Cell stem cell Sep, 2011 | Pubmed ID: 21885017
FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples.
Leukemia research Jan, 2012 | Pubmed ID: 21917313
Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.
Blood Nov, 2011 | Pubmed ID: 21917753
The spliceosome as an indicted conspirator in myeloid malignancies.
Cancer cell Oct, 2011 | Pubmed ID: 22014568
Clinical implications of novel mutations in epigenetic modifiers in AML.
Hematology/oncology clinics of North America Dec, 2011 | Pubmed ID: 22093580
Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.
Current hematologic malignancy reports Mar, 2012 | Pubmed ID: 22170482
Nuclear JAK2.
Blood Dec, 2011 | Pubmed ID: 22194397
Molecular alterations underlying eosinophilic and mast cell malignancies.
Discovery medicine Dec, 2011 | Pubmed ID: 22204765
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Nature Mar, 2012 | Pubmed ID: 22343901
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
The New England journal of medicine Mar, 2012 | Pubmed ID: 22417203
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
Blood May, 2012 | Pubmed ID: 22431577
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
American journal of hematology May, 2012 | Pubmed ID: 22460584
Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice.
Hematology (Amsterdam, Netherlands) Apr, 2012 | Pubmed ID: 22507776
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.
Leukemia & lymphoma Feb, 2013 | Pubmed ID: 22680765
Refining the prognostic importance of the diversity of FLT3 internal tandem duplications.
Leukemia & lymphoma Jan, 2013 | Pubmed ID: 22775313
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Nature Sep, 2012 | Pubmed ID: 22820254
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.
Blood Sep, 2012 | Pubmed ID: 22855599
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Sep, 2012 | Pubmed ID: 22869879
Loss of the tumor suppressor BAP1 causes myeloid transformation.
Science (New York, N.Y.) Sep, 2012 | Pubmed ID: 22878500
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
Cancer cell Aug, 2012 | Pubmed ID: 22897849
The role of mutations in epigenetic regulators in myeloid malignancies.
Nature reviews. Cancer Sep, 2012 | Pubmed ID: 22898539
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Leukemia research Dec, 2012 | Pubmed ID: 22938832
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.
Nature genetics Nov, 2012 | Pubmed ID: 23001125
Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.
Hematology/oncology clinics of North America Oct, 2012 | Pubmed ID: 23009937
Epigenetic alterations in hematopoietic malignancies.
International journal of hematology Oct, 2012 | Pubmed ID: 23015417
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
European urology May, 2013 | Pubmed ID: 23036577
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis.
Leukemia research Jan, 2013 | Pubmed ID: 23102703
Progression of RAS-mutant leukemia during RAF inhibitor treatment.
The New England journal of medicine Dec, 2012 | Pubmed ID: 23134356
Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia.
Acta haematologica , 2013 | Pubmed ID: 23147462
Interpreting new molecular genetics in myelodysplastic syndromes.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program , 2012 | Pubmed ID: 23233561
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Haematologica Apr, 2013 | Pubmed ID: 23242596
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
The Journal of biological chemistry Feb, 2013 | Pubmed ID: 23264629
HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders.
The Journal of experimental medicine Feb, 2013 | Pubmed ID: 23319699
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.
Haematologica Jun, 2013 | Pubmed ID: 23349305
Notch pathway activation targets AML-initiating cell homeostasis and differentiation.
The Journal of experimental medicine Feb, 2013 | Pubmed ID: 23359070
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia.
Nature medicine Apr, 2013 | Pubmed ID: 23502961
Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression.
Cancer cell Mar, 2013 | Pubmed ID: 23518350
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.
Blood Jun, 2013 | Pubmed ID: 23632888
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.
Blood May, 2013 | Pubmed ID: 23640996
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
Blood Jun, 2013 | Pubmed ID: 23641016
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.
Cancer cell May, 2013 | Pubmed ID: 23680150
Importance of genetics in the clinical management of chronic myelomonocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jul, 2013 | Pubmed ID: 23690427
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
Blood Aug, 2013 | Pubmed ID: 23782935
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Blood Sep, 2013 | Pubmed ID: 23926298
Detection of an NRAS mutation in Erdheim-Chester disease.
Blood Aug, 2013 | Pubmed ID: 23929840
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Leukemia & lymphoma Feb, 2014 | Pubmed ID: 24206094
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
The Journal of clinical investigation Nov, 2013 | Pubmed ID: 24216483
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.
The Journal of experimental medicine Nov, 2013 | Pubmed ID: 24218140
The importance of subclonal genetic events in MDS.
Blood Nov, 2013 | Pubmed ID: 24263953
Focus on the epigenome in the myeloproliferative neoplasms.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program , 2013 | Pubmed ID: 24319229
Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations.
Haematologica Feb, 2014 | Pubmed ID: 24497555
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
Genes & development Mar, 2014 | Pubmed ID: 24589777
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.
Cancer discovery May, 2014 | Pubmed ID: 24589925
Recent discoveries in molecular characterization of acute myeloid leukemia.
Current hematologic malignancy reports Jun, 2014 | Pubmed ID: 24609756
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
Blood May, 2014 | Pubmed ID: 24740812
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.
Haematologica May, 2014 | Pubmed ID: 24790057
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.
Blood May, 2014 | Pubmed ID: 24850756
Hematopoietic Stem Cell Origin of BRAFV600E Mutations in Hairy Cell Leukemia.
Science translational medicine May, 2014 | Pubmed ID: 24871132
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myeloid leukemia.
Molecular cancer therapeutics Jun, 2014 | Pubmed ID: 24934933
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.
Blood Jun, 2014 | Pubmed ID: 24973361
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados